
临床神经研究团队 | |
姓名 | 王 培宁 |
电子邮件 | pnwang@vghtpe.gov.tw |
POSITION TITLE/AFFILIATIONS | Professor/ Department of Neurology, School of Medicine, National Yang-Ming Chiao Tung University Attending Physicision/ Department of Neurology, Taipei Veterans General Hospital |
EDUCATION/TRAINING | 1983-1990 MedicineMD, National Yang-Ming University, Taipei, Taiwan 1992-1997 Resident in Neurology, Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan 2003-2004 Behavior Neurology FellowshipMemory and Aging Center, University of California, San Francisco, USA |
Service | 阳明大学医学系毕业,曾任美国加州大学旧金山分校(UCSF) 记忆和老化研究中心临床研究员, 现任阳明大学神经科教授,台北荣民总医院失智症治疗及研究中心主任,Journal of Alzheimer’s disease 、Journal of Clinical Gerontology and Geriatrics、Plos one编辑,台湾临床失智症学会理事,台湾失智症协会理事,台湾神经学会行为神经学组,台湾老年学暨老年医学会学术委员会委员。 临床和学术专长为失智症、年轻型失智症,神经退化性疾病,老年神经学,神经影像学和行为神经学。 |
职称 | 台北荣民总医院 一般神经科 主治医师 |
研究专长 | The biomarkers of dementia, especially Alzheimer disease (AD) in Taiwan |
研究概况 | My research is focus on investigating the biomarkers of dementia, especially Alzheimer disease (AD) in Taiwan. In the earlier years, we made efforts on establish the validity of the Chinese-version neuropsychological tests to make a accurate early diagnosis of mild AD and mild cognitive impairment (MCI). We published the presentations of verbal memory, executive function, language functions and daily functions in MCI and mild AD. Recently, we cooperated with experts in genetics, pharmacology, biochemistry, and neuroimaging for extending our research to the bio-molecular and neuroimaging aspects of dementia. As PI or co-Investigator on several national and hospital funded grants, I laid the groundwork for the proposed research by investigating biomarkers for early diagnosis of Alzheimer’s disease and prediction the progress from aging to mild cognitive impairment and dementia. We found the rate of hippocampal atrophy was note only higher in progressive MCI, but also in stable MCI. Longitudinally evaluating hippocampal volume may be more sensitive than neuropsychological tests to detect the progression of MCI. Last year, we published the special patterns of axonal degeneration and myelin degradation in different brain regions in MCI and mild AD. In the next few years, our research focus will be placed on inspecting the trajectory of different biomarkers from preclinical AD, MCI due to AD, to dementia due to AD. |